Breaking News
Get 50% Off 0
💎 Bargain Hunter: Undervalued stocks with massive upside potential
Get the list
Close

Proteomics International Laboratories Ltd (PIQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.390 +0.010    +2.63%
02:28:59 - Delayed Data. Currency in AUD
Type:  Equity
Market:  Australia
ISIN:  AU000000PIQ0 
  • Volume: 102,714
  • Bid/Ask: 0.385 / 0.395
  • Day's Range: 0.385 - 0.395
Proteomics Intl Labs 0.390 +0.010 +2.63%

Proteomics International Laboratories Ltd Company Profile

 
Get an in-depth profile of Proteomics International Laboratories Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

-

Equity Type

ORD

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for diabetic kidney disease in type 1 diabetes; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy; and Giardia, a causing gastroenteritis. The company also offers analytical services, such as pharmacokinetic testing, biomarker discovery, protein analysis, project consultation, and specialist contract research. Proteomics International Laboratories Ltd was founded in 2001 and is headquartered in Perth, Australia.

Contact Information

Address QEII Medical Centre QQ Block
6 Verdun Street Nedlands Perth, 6009
Australia
Phone 61 8 9389 1992
Fax -

Top Executives

Name Age Since Title
Terry Sweet 74 2014 Independent Non-Executive Chairman
Merlin Thomas - 2022 Member of Clinical Advisory Board
Eleuterio Ferrannini - 2022 Member of Clinical Advisory Board
Michael Shanik - 2022 Member of Clinical Advisory Board
Alexander Turchin - 2022 Member of Clinical Advisory Board
Tim Davis - 2022 Member of Clinical Advisory Board
Davida F. Kruger - - Member of Clinical Advisory Board
James Williams - 2024 Independent Non- Executive Director
Paul House 54 2017 Independent Non-Executive Director
Neville Gardiner - 2021 Independent Non-Executive Director
Richard John Lipscombe - 2001 Co-Founder, MD & Director
Aaron Brinkworth - 2024 Independent Non-Executive Director
Prasad Iyer - 2025 Member of Clinical Advisory Board
Andrew Chang - 2025 Member of Clinical Advisory Board
Krish Ragunath - 2025 Member of Clinical Advisory Board
Jacques Bergman - 2025 Member of Clinical Advisory Board
Robert Odze - 2025 Member Clinical Advisory Board
Daniela Molena - 2025 Member of Clinical Advisory Board
Hugh Barr - 2025 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PIQ Comments

Write your thoughts about Proteomics International Laboratories Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email